Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 201–300 of 1,002
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Czarnowicki, T., He, H., Canter, T., Han, J., Lefferdink, R., Erickson, T., Rangel, S., Kameyama, N., Kim, H. J., Pavel, A. B., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.031 · Cited by 118
“that even adolescents have a different profile from adults, possibly contributing to the somewhat lower response to the recently approved IL-4 receptor a antagonist dupilumab in adolescents versus adults.(30,31) Immune responses at birth are immature,(10) with decreases in frequencies of naive T cells in healthy child…”
BackgroundSelf-citationVandeghinste, N., Klattig, J., Jagerschmidt, C., Lavazais, S., Marsais, F., Haas, J. D., Auberval, M., Lauffer, F., Moran, T., Ongenaert, M., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.036 · Cited by 115
“In AD patients, recent Phase 3 data of dupilumab clinically underscore the important role of Th2 cells in disease pathogenesis, because IL-4Ra blockade, which affects IL-4 and IL-13 signaling, shows remarkable efficacy (Simpson et al., 2016).”
BackgroundDendritic Cell-Mediated Th2 Immunity and Immune Disorders
Kumar, S., Ashraf, M. U., Jeong, Y., & Bae, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092159 · Cited by 130
Mitamura, Y., Reiger, M., Kim, J., Xiao, Y., Zhakparov, D., Tan, G., Rückert, B., Rinaldi, A. O., Baerenfaller, K., Akdiş, M., et al. (2023) · Allergy · doi:10.1111/all.15781 · Cited by 131
Cork, M. J., Eckert, L., Simpson, E. L., Armstrong, A. W., Barbarot, S., Puig, L., Girolomoni, G., de Bruin-Weller, M. S., Wollenberg, A., Kataoka, Y., et al. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1612836 · Cited by 122
Self-citationBiologics for the Use in Chronic Spontaneous Urticaria: When and Which
Maurer, M., Khan, D. A., Komi, D. E. A., & Kaplan, A. P. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.043 · Cited by 114
Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis
Mack, M. R., Brestoff, J. R., Berrien-Elliott, M. M., Trier, A. M., Yang, T.-L. B., McCullen, M., Collins, P. L., Niu, H., Bodet, N. D., Wagner, J. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1005 · Cited by 111
Jiao, W., Lin, J., Deng, Y., Ji, Y., Liang, C., Wei, S., Xi, J., & Yan, F. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03312-3 · Cited by 141
Kim, B., Sun, K., Papp, K. A., Venturanza, M. E., Nasir, A., & Kuligowski, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.009 · Cited by 114
Vieyra-Garcia, P. A., & Wolf, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107784 · Cited by 125
Weidinger, S., Bieber, T. R. M., Cork, M. J., Reich, A., Wilson, R. J., Quaratino, S., Stebegg, M., Brennan, N., Gilbert, S., O’Malley, J. T., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad240 · Cited by 111
Self-citationWorm, M., Bauer, A., Elsner, P., Mahler, V., Molin, S., & Nielsen, T. S. S. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18469 · Cited by 107
Self-citationTargeting IL-4 for the Treatment of Atopic Dermatitis
Chiricozzi, A., Maurelli, M., Peris, K., & Girolomoni, G. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s260370 · Cited by 120
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis
Narla, S., Silverberg, J. I., & Simpson, E. L. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.017 · Cited by 110
Self-citationKelly, K. A., Balogh, E. A., Kaplan, S. G., & Feldman, S. R. (2021) · Children · doi:10.3390/children8111057 · Cited by 111
“Moreover, the associations do not necessarily imply causation [32].”
BackgroundBreiteneder, H., Diamant, Z., Eiwegger, T., Fokkens, W. J., Traidl‐Hoffmann, C., Nadeau, K., O’Hehir, R. E., O’Mahony, L., Pfaar, O., Torres, M. J., et al. (2019) · Allergy · doi:10.1111/all.13851 · Cited by 107
The IL‐13–OVOL 1–FLG axis in atopic dermatitis
Furue, K., Ito, T., Tsuji, G., Ulzii, D., Vu, Y. H., Kido‐Nakahara, M., Nakahara, T., & Furue, M. (2019) · Immunology · doi:10.1111/imm.13120 · Cited by 107
Mandlik, D. S., & Mandlik, S. K. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1889583 · Cited by 129
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L. M., Zeitvogel, J., & Werfel, T. (2021) · Allergy · doi:10.1111/all.14853 · Cited by 116
“Inflammatory skin march” in atopic dermatitis and psoriasis
Furue, M., & Kadono, T. (2017) · Inflammation Research · doi:10.1007/s00011-017-1065-z · Cited by 123
Beck, L. A., Deleuran, M. S., Bissonnette, R., de Bruin-Weller, M. S., Galus, R., Nakahara, T., Seo, S. J., Khokhar, F. A., Vakil, J., Xiao, J., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00685-0 · Cited by 120
“Safety data reported here are consistent with data from previous controlled studies of dupilumab up to 52 weeks [10, 12, 19], and common AEs (nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions) are consistent with the known safety profile of dupi…”
BackgroundResultSelf-citationEckert, L., Gupta, S., Amand, C., Gadkari, A., Mahajan, P., & Gelfand, J. M. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.002 · Cited by 105
Self-citationTopf, J. M., Wooldridge, T. D., McCafferty, K., Schömig, M., Csiky, B. S., Zwiech, R., Wen, W., Bhaduri, S., Munera, C. L., Lin, R., et al. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100512 · Cited by 104
“approved therapeutic for pruritic conditions.(26) The placebo response was higher in KALM-2 than in KALM-1 with respect to the proportion of participants who achieved a ≥3-point or ≥4-point reduction from baseline in the weekly mean WI-NRS score at week 12.”
BackgroundDupilumab: Mechanism of action, clinical, and translational science
McCann, M. R., Kosloski, M. P., Xu, C. R., Davis, J. D., & Kamal, M. A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13899 · Cited by 128
“19,20 Pooled data from three monotherapy trials showed dupilumab 300 mg Q2W resulted in higher rates of injection site reactions (10% vs 5”
BackgroundDupilumab: Basic aspects and applications to allergic diseases
Matsunaga, K., Katoh, N., Fujieda, S., Izuhara, K., & Oishi, K. (2020) · Allergology International · doi:10.1016/j.alit.2020.01.002 · Cited by 109
Caminati, M., Olivieri, B., Dama, A., Micheletto, C., Paggiaro, P., Pinter, P., Senna, G., & Schiappoli, M. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2090342 · Cited by 108
Evaluation of Dupilumab in Patients With Bullous Pemphigoid
Zhao, L., Wang, Q., Liang, G., Zhou, Y., Yiu, N., Yang, B., Zhang, G., Li, W., Feng, S., Shang, P., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2428 · Cited by 103
Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre
Olesen, C. M., Holm, J. G., Nørreslet, L. B., Serup, J. V., Thomsen, S. F., & Agner, T. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15609 · Cited by 102
Bachert, C., Hellings, P., Mullol, J., Hamilos, D., Gevaert, P., Naclerio, R., Joish, V., Chao, J., Mannent, L., Amin, N., et al. (2019) · Allergy. European Journal of Allergy and Clinical Immunology · doi:10.1111/all.13984 · Cited by 93
Self-citationThe socioeconomics of atopic dermatitis
Chung, J., & Simpson, E. L. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.12.017 · Cited by 112
Self-citationShi, V. Y., Bhutani, T., Fonacier, L. S., Deleuran, M. S., Shumack, S. P., Valdez, H., Zhang, F., Chan, G. L., Cameron, M. C., & Yin, N. C. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.04.009 · Cited by 101
Self-citationGuttman‐Yassky, E., Hanifin, J. M., Boguniewicz, M., Wollenberg, A., Bissonnette, R., Purohit, V. S., Kilty, I., Tallman, A. M., & Zielinski, M. A. (2018) · Experimental Dermatology · doi:10.1111/exd.13808 · Cited by 110
Self-citationCharacterizing dupilumab facial redness: A multi-institution retrospective medical record review
Waldman, R. A., DeWane, M. E., Sloan, B., & Grant-Kels, J. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.026 · Cited by 100
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
Zheng, S., & Zeng, Y. (2023) · Dermatology · doi:10.1159/000530608 · Cited by 111
Glickman, J. W., Dubin, C., Renert‐Yuval, Y., Dahabreh, D., Kimmel, G. W., Auyeung, K. L., Estrada, Y. D., Singer, G., Krueger, J. G., Pavel, A. B., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.138 · Cited by 98
Self-citationDupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study
Patruno, C., Napolitano, M., Argenziano, G., Peris, K., Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17094 · Cited by 98
Nakashima, C., Ishida, Y., Kitoh, A., Otsuka, A., & Kabashima, K. (2019) · Experimental Dermatology · doi:10.1111/exd.14014 · Cited by 100
Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications
Kortekaas Krohn, I., Shikhagaie, M. M., Golebski, K., Bernink, J. H., Breynaert, C., Creyns, B., Diamant, Z., Fokkens, W. J., Gevaert, P., Hellings, P., et al. (2018) · Allergy · doi:10.1111/all.13340 · Cited by 96
“Anti-IL4Ra seems promising for the management of AD.(115) Combination approaches will be required to”
BackgroundHashimoto, T., Yokozeki, H., Karasuyama, H., & Satoh, T. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.11.009 · Cited by 96
Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis
Ravnborg, N., Ambikaibalan, D., Agnihotri, G., Price, S., Rastogi, S., Patel, K. R., Singam, V., Andersen, Y. M. F., Halling, A., Silverberg, J. I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.055 · Cited by 110
Self-citationPrecision Medicine in Chronic Rhinosinusitis with Nasal Polyps
Avdeeva, K. S., & Fokkens, W. J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0776-8 · Cited by 102
Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
de Wijs, L. E. M., Bosma, A. L., Erler, N. S., Hollestein, L. M., Gerbens, L. A. A., Middelkamp-Hup, M. A., Kunkeler, A. C. M., Nijsten, T. E. C., Spuls, P. I., & Hijnen, D. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18179 · Cited by 101
Fargnoli, M. C., Esposito, M., Ferrucci, S. M., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., et al. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1682503 · Cited by 100
“The percentage of patients with EASI50 and EASI75 at week 16 was similar to that observed in clinical trials investigating dupilumab in combination with topical corticosteroids [8,9] while it was higher than in trials using dupilumab as monotherapy [7].”
ResultThe Neuroimmune Axis in Skin Sensation, Inflammation, and Immunity
Trier, A. M., Mack, M. R., & Kim, B. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801473 · Cited by 103
Kim, B., Rothenberg, M. E., Sun, X., Bachert, C., Artis, D., Zaheer, R. S., Deniz, Y. M., Rowe, P., & Cyr, S. L. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.017 · Cited by 100
Ariëns, L. F. M., van der Schaft, J., Spekhorst, L. S., Bakker, D. S., Romeijn, G. L. E., Kouwenhoven, T. A., Kamsteeg, M., Voorberg, A. N., Oosting, A. J., de Ridder, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.08.127 · Cited by 99
“Physician- and patient-reported outcomes at week 16 are consistent with those reported in previous phase 3 clinical trials and daily practice studies.(1-3,6-8,17) Concerning long-term outcome, the effectiveness in our daily practice study is comparable to clinical outcomes of the 52-week, randomized, double-blinded, p…”
BackgroundResultInfluentialType 2 inflammation and biological therapies in asthma: Targeted medicine taking flight
Howell, I., Howell, A., & Pavord, I. D. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221212 · Cited by 100
Alopecia Areata: Current Treatments and New Directions
Dahabreh, D., Jung, S., Renert‐Yuval, Y., Bar, J., DUCA, E. D., & Guttman‐Yassky, E. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00808-1 · Cited by 110
“It is FDA-approved for treating atopic dermatitis (AD) and other diseases mediated by type 2 immune activation [140–142].”
BackgroundSelf-citationManagement of Itch in Atopic Dermatitis
Pavlis, J. M., & Yosipovitch, G. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0335-4 · Cited by 101
“in treating AD and rapidly improving AD-associated pruritus [27].”
InfluentialA review of dupilumab in the treatment of atopic diseases
Thibodeaux, Q. G., Smith, M. R., Ly, K., Beck, K. M., Liao, W. J., & Bhutani, T. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1582403 · Cited by 100
“Importantly, this increased risk has not been seen in the trials for asthma and chronic sinusitis.(10) Episodes of conjunctivitis have generally been mild to moderate in severity and were rarely the cause of drug discontinuation.”
BackgroundInfluentialThe Regulatory Effects of Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses
Egholm, C., Heeb, L. E. M., Impellizzieri, D., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02507 · Cited by 103
“Moreover, treatment of moderate-to-severe AD patients with the IL-4Rα-blocking antibody Dupilumab has been shown to not only significantly decrease disease burden, but also lower the incidence of skin infections (84, 116, 117).”
BackgroundAl‐Janabi, A., Foulkes, A., Mason, K. J., Smith, C. H., Griffiths, C. E. M., & Warren, R. B. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16246 · Cited by 96
IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma
Husna, S. M. N., Shukri, N. M., Ashari, N. S. M., & Wong, K. K. (2022) · PeerJ · doi:10.7717/peerj.13444 · Cited by 109
Drucker, A. M., Lam, M., Prieto‐Merino, D., Malek, R., Ellis, A. G., Yiu, Z. Z. N., Rochwerg, B. N., Giorgio, S. D., Arents, B. W. M., Mohan, T., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.2192 · Cited by 115
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Sun, X., Chen, Z., Akinlade, B. K., Boklage, S., Guillemin, I., Kosloski, M. P., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19460 · Cited by 94
Self-citationDupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Kychygina, A., Cassagne, M., Tauber, M., Galiacy, S. D., Paul, C. F., Fournié, P., & Simon, M. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08934-0 · Cited by 103
“The literature describes cases of rosacea-like skin lesions and facial redness (eczematous facial rash) in dupilumabtreated patients [33, 56–66] (Table 1), symptoms that were not initially described in the dupilumab AD clinical trials [3].”
BackgroundCurrent and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
Haddad, E., Cyr, S. L., Arima, K., McDonald, R. A., Levit, N. A., & Nestle, F. O. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00737-7 · Cited by 102
Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease
Farzanfar, D., Dowlati, Y., French, L. E., Lowes, M. A., & Alavi, A. (2018) · Skin Pharmacology and Physiology · doi:10.1159/000490002 · Cited by 98
Paller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Lockshin, B., Kosloski, M. P., Kamal, M. A., Davis, J. D., Sun, X., Pirozzi, G., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16928 · Cited by 106
Self-citationThe Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma
Nakagome, K., & Nagata, M. (2024) · Biomolecules · doi:10.3390/biom14050546 · Cited by 108
“Dupilumab is effective for treating atopic dermatitis [103] and is prescribed in the clinical setting.”
BackgroundLiu, Z., Chen, J., Cheng, L., Li, H., Liu, S., Lou, H., Shi, J., Sun, Y., Wang, D., Wang, C., et al. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.2.176 · Cited by 97
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis
Busse, W. W., Maspero, J. F., Lü, Y., Corren, J., Hanania, N. A., Chipps, B. E., Katelaris, C. H., FitzGerald, J. M., Quirce, S., Ford, L. B., et al. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.05.026 · Cited by 98
Self-citationThe use of biologics in food allergy
Fiocchi, A. G., Vickery, B. P., & Wood, R. A. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13897 · Cited by 96
Buchheit, K. M., Sohail, A., Hacker, J. J., Maurer, R., Gakpo, D. H., Bensko, J. C., Taliaferro, F., Ordovás-Montañés, J., & Laidlaw, T. M. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.007 · Cited by 97
European Guideline ( EuroGuiDerm ) on atopic eczema: Living update
Wollenberg, A., Kinberger, M., Arents, B. W. M., ASZODI, N., Barbarot, S., Bieber, T. R. M., Brough, H. A., Calzavara‐Pinton, P., Christen‐Zaech, S., Deleuran, M. S., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20639 · Cited by 127
Self-citationModulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer
Marković, I., & Savvides, S. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01557 · Cited by 86
Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
Maudinet, A., Law-Koune, S., Duretz, C., Lasek, A., Modiano, P., & Tran, T. H. C. (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-0191-9 · Cited by 87
Min, M. S., Wu, J., He, H., Sanz-Cabanillas, J. L., DUCA, E. D., Zhang, N., Renert‐Yuval, Y., Pavel, A. B., Lebwohl, M., & Guttman‐Yassky, E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.028 · Cited by 95
Self-citationA key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis
Bitton, A., Avlas, S., Reichman, H., Itan, M., Karo‐Atar, D., Azouz, N. P., Rozenberg, P., Diesendruck, Y., Nahary, L., Rothenberg, M. E., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaw2938 · Cited by 90
“The importance of IL-4, IL-13, and their associated receptors in AD is best exemplified by the ongoing pursuit to pharmacologically target these cytokines and/or their signaling components in AD (5, 6).”
BackgroundImai, Y., Yasuda, K., Nagai, M., Kusakabe, M., Kubo, M., Nakanishi, K., & Yamanishi, K. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.04.016 · Cited by 93
Bakker, D. S., van der Wal, M., Heeb, L. E. M., Giovannone, B., Asamoah, M., Delemarre, E. M., Drylewicz, J., Nierkens, S., Boyman, O., de Bruin-Weller, M. S., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.022 · Cited by 94
Wollenberg, A., Beck, L. A., de Bruin Weller, M., Simpson, E. L., Imafuku, S., Boguniewicz, M., Zachariae, R., Olsen, C. K., & Thyssen, J. P. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20810 · Cited by 86
Self-citationUpdate on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs
Nuttall, T. J., Marsella, R., Rosenbaum, M. R., Gonzales, A. J., & Fadok, V. A. (2019) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.254.11.1291 · Cited by 135
“48 It has been confirmed as a key cytokine in the development of early skin lesions of dogs with atopic dermatitis.”
BackgroundTreatment resistant atopic dermatitis: challenges and solutions
Johnson, B. B., Franco, A. I., Beck, L. A., & Prezzano, J. C. (2019) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s163814 · Cited by 96
“Dupilumab Dupilumab is a fully humanized monoclonal antibody against the shared alpha subunit of IL-4 and IL-13 receptors, which blocks the actions of these two canonical T-helper type 2 (Th2) cytokines that are commonly found in the skin of AD patients.(37) Dupilumab was FDA approved in March 2017 for”
BackgroundSelf-citationSkin barrier defects in atopic dermatitis: From old idea to new opportunity
Yoshida, T., Beck, L. A., & Benedetto, A. D. (2021) · Allergology International · doi:10.1016/j.alit.2021.11.006 · Cited by 102
Self-citationAtopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options
Bieber, T. R. M., Paller, A. S., Kabashima, K., Feely, M. A., Rueda, M. J., Terres, J. A. R., & Wollenberg, A. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18225 · Cited by 103
Self-citationOX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
Croft, M., Esfandiari, E., Chong, C., Hsu, H., Kabashima, K., Kricorian, G., Warren, R. B., Wollenberg, A., & Guttman‐Yassky, E. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00838-9 · Cited by 97
“…agents as needed) or tralokinumab (combined with topical corticosteroid) could not achieve clear or almost clear skin after 16 weeks of treatment [56, 57] and in a retrospective cohort study, 35% of patients lost or partially lost the response to dupilumab after 12 months of treatment [58, 59].”
BackgroundSelf-citationBasophils and their effector molecules in allergic disorders
Miyake, K., Shibata, S., Yoshikawa, S., & Karasuyama, H. (2020) · Allergy · doi:10.1111/all.14662 · Cited by 100
Soria, A., Du-Thanh, A., Sénéschal, J., Jachiet, M., Staumont-Sallé, D., & Barbarot, S. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.2613 · Cited by 84
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents
Licari, A., Castagnoli, R., Marseglia, A., Olivero, F., Votto, M., Ciprandi, G., & Marseglia, G. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00387-2 · Cited by 91
Marschall, P., Wei, R., Segaud, J., Yao, W., Hener, P., German, B., Meyer, P., Hugel, C., Silva, G. A. D., Braun, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.006 · Cited by 94
Drug-induced alopecia after dupilumab therapy
Flanagan, K., Sperling, L. C., & Lin, J. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.10.010 · Cited by 83
“Most commonly reported side effects include injection site reactions, eye and eyelid inflammation, and nasopharyngitis.(1,2) This case report highlights a patient who experienced druginduced alopecia at 18 weeks on dupilumab.”
BackgroundAtopic dermatitis and psychosocial comorbidities
Kage, P., Simon, J., & Treudler, R. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14029 · Cited by 99
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
“Dupilumab also significantly reduced the weekly average of daily peak pruritus on the numerical rating scale (NRS) from 0 (= no itch) to 10 (= worst imaginable itch) by about 50% as compared to about 20% in controls (56).”
BackgroundPaller, A. S., Bansal, A., Simpson, E. L., Boguniewicz, M., Blauvelt, A., Siegfried, E. C., Guttman‐Yassky, E., Hultsch, T., Chen, Z., Mina‐Osorio, P., et al. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00478-y · Cited by 84
Self-citationZuberbier, T., Ansari, Z. A., Latiff, A. H. A., Abuzakouk, M. M., Jesus, M. S. A., Agondi, R. C., Al-Ahmad, M. S., Alangari, A., Alhameli, H. A., Alonso-Bello, C. D., et al. (2026) · Allergy · doi:10.1111/all.70210 · Cited by 139
Insights into atopic dermatitis gained from genetically defined mouse models
Nakajima, S., Nomura, T., Common, J., & Kabashima, K. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.014 · Cited by 86
Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis
Snast, I., Reiter, O., Hodak, E., Friedland, R., Mimouni, D., & Leshem, Y. A. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0324-7 · Cited by 89
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
Wang, F., Tang, X., Wei, C., Xu, L., Mao, H. Z., & Luo, F. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.01.016 · Cited by 89
Nomura, T., Honda, T., & Kabashima, K. (2018) · International Immunology · doi:10.1093/intimm/dxy015 · Cited by 80
Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults
Barrett, A. M., Hahn-Pedersen, J. H., Kragh, N., Evans, E., & Gnanasakthy, A. (2019) · Patient · doi:10.1007/s40271-019-00373-y · Cited by 79
A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
Kamata, M., & Tada, Y. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100042 · Cited by 86
“…placebo-controlled, phase 3 trials of dupilumab in adult patients with moderate-to-severe AD whose disease was inadequately controlled by topical treatment were conducted: LIBERTY AD SOLO 1, SOLO 2, CHRONOS, and CAFÉ (Blauvelt et al., 2017; de Bruin-Weller et al., 2018b; Simpson et al., 2016b).”
BackgroundMethodInfluentialBieber, T. R. M., Reich, K., Paul, C. F., Tsunemi, Y., Augustin, M., Lacour, J. ‐., Ghislain, P., Dutronc, Y., Liao, R., Yang, F. E., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21630 · Cited by 89
Self-citationSimpson, E. L., Merola, J. F., Silverberg, J. I., Reich, K., Warren, R. B., Staumont-Sallé, D., Girolomoni, G., Papp, K. A., de Bruin-Weller, M. S., Thyssen, J. P., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21867 · Cited by 89
Self-citationOX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
Lé, A. M., & Torres, T. R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122753 · Cited by 90
“Dupilumab, a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors, changed the AD treatment paradigm as it was in 2017 as the first biological drug approved for the treatment of AD [5,6].”
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Ariëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3212 · Cited by 79
Wang, C., Kraus, C. N., Patel, K. G., Ganesan, A. K., & Grando, S. A. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14573 · Cited by 78
Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
Popiela, M., Barbara, R., Turnbull, A. M. J., Corden, E., Martinez-Falero, B. S., O’Driscoll, D., Ardern‐Jones, M. R., & Hossain, P. N. (2021) · Eye · doi:10.1038/s41433-020-01379-9 · Cited by 86
Overview of Atopic Dermatitis in Different Ethnic Groups
Chiricozzi, A., Maurelli, M., Calabrese, L., Peris, K., & Girolomoni, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072701 · Cited by 89
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.